Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-MAP2K4 Antibody (R3L42)

Catalog #:   RHE46003 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IHC, WB
Accession: P45985
Overview

Catalog No.

RHE46003

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

MEK 4, MEK4, SAPK kinase 1, JNKK, c-Jun N-terminal kinase kinase 1, SEK1, JNK-activating kinase 1, MAPK/ERK kinase 4, MAPKK 4, SERK1, SKK1, SAPKK-1, SAPK/ERK kinase 1, PRKMK4, MKK4, MAP kinase kinase 4, MAP2K4, Dual specificity mitogen-activated protein kinase kinase 4, SAPKK1, Stress-activated protein kinase kinase 1, JNKK1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P45985

Applications

ELISA, FCM, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3L42

Data Image
  • Flow Cytometry
    Flow cytometric analysis of K562 cells using MAP2K4 mouse mAb (green) and negative control (purple).
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human muscle tissues using MAP2K4 mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using MAP2K4 mouse mAb against HepG2 (1), K562 (2), and HEK293 (3) cell lysate.
References

Tissue-origin transcriptomic interactions as indicators of inflammatory aging and aging gene discovery., PMID:40527241

E203K mutation in MAP2K1 (MEK1) causes acquired resistance to PD-1 blockade but responds to trametinib: a case report., PMID:39806853

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis., PMID:33495600

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway., PMID:33436306

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., PMID:33043759

Immunoglobulin deficiency associated with a MAP2K1-related mutation causing cardio-facio-cutaneous syndrome., PMID:32866538

Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer., PMID:32805066

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer., PMID:32047001

Genomic and immune profiling of pre-invasive lung adenocarcinoma., PMID:31784532

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., PMID:31227518

Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae., PMID:30923995

CRISPR/Cas9-Mediated Knockout of MicroRNA-744 Improves Antibody Titer of CHO Production Cell Lines., PMID:30802343

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer., PMID:30777101

Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner., PMID:30394679

Anti-β2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression., PMID:30368780

Alterations of MEK1/2-ERK1/2, IFNγ and Smad2/3 associated Signalling pathways during cryopreservation of ASCs affect their differentiation towards VSMC-like cells., PMID:30273905

Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand., PMID:30250119

The effect of human herpesvirus 6B infection on the MAPK pathway., PMID:30130603

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma., PMID:30115691

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?, PMID:29851931

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment., PMID:29767411

Acetylation regulates the MKK4-JNK pathway in T cell receptor signaling., PMID:29248490

Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations., PMID:29107340

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia., PMID:28918710

MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing., PMID:28733031

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS., PMID:28592615

Interaction of molecular alterations with immune response in melanoma., PMID:28543700

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma., PMID:28543695

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies., PMID:28236768

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer., PMID:27636997

Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals., PMID:27441275

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment., PMID:27341591

A Phos-tag SDS-PAGE method that effectively uses phosphoproteomic data for profiling the phosphorylation dynamics of MEK1., PMID:27169363

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer., PMID:26644315

Hairy cell leukaemia-variant: Disease features and treatment., PMID:26614904

The genomic landscape of response to EGFR blockade in colorectal cancer., PMID:26416732

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells., PMID:26384788

Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway., PMID:25825984

Interleukin-1 Acts via the JNK-2 Signaling Pathway to Induce Aggrecan Degradation by Human Chondrocytes., PMID:25776267

Brominated flame retardants, tetrabromobisphenol A and hexabromocyclododecane, activate mitogen-activated protein kinases (MAPKs) in human natural killer cells., PMID:25341744

Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9., PMID:25326806

Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases., PMID:24681949

The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival., PMID:24445144

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias., PMID:24241536

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines., PMID:24192080

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients., PMID:24170544

New targets and new mechanisms in lung cancer., PMID:25184262

Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin., PMID:22242821

Stress-activated kinase pathway alteration is a frequent event in bladder cancer., PMID:22154358

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells., PMID:22086413

Datasheet

Document Download

Anti-MAP2K4 Antibody (R3L42).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MAP2K4 Antibody (R3L42) [RHE46003]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only